Abstract
The blood-brain barrier (BBB), a dynamic and complex barrier formed by endothelial cells, can impede the entry of unwanted substances – pathogens and therapeutic molecules alike – into the central nervous system (CNS) from the blood circulation. Taking into account the fact that CNS-related diseases are the largest and fastest growing unmet medical concern, many potential protein- and nucleic acid-based medicines have been developed for therapeutic purposes. However, due to their poor ability to cross the BBB and the plasma membrane, the above-mentioned bio-macromolecules have limited use in treating neurological diseases. Finding effective, safe, and convenient ways to deliver therapeutic molecules into the CNS is thus urgently required. In recent decades, much effort has been expended in the development of drug delivery technologies, of which cell-penetrating peptides (CPPs) have the most promising potential. The present review covers the latest advances in CPP delivery technology, and provides an update on their use in CNS-targeted drug delivery.
Keywords: Central nervous system, blood-brain barrier, cell-penetrating peptides, drug delivery
Current Neuropharmacology
Title:Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Volume: 11 Issue: 2
Author(s): Li-Li Zou, Jie-Lan Ma, Tao Wang, Tang-Bin Yang and Chang-Bai Liu
Affiliation:
Keywords: Central nervous system, blood-brain barrier, cell-penetrating peptides, drug delivery
Abstract: The blood-brain barrier (BBB), a dynamic and complex barrier formed by endothelial cells, can impede the entry of unwanted substances – pathogens and therapeutic molecules alike – into the central nervous system (CNS) from the blood circulation. Taking into account the fact that CNS-related diseases are the largest and fastest growing unmet medical concern, many potential protein- and nucleic acid-based medicines have been developed for therapeutic purposes. However, due to their poor ability to cross the BBB and the plasma membrane, the above-mentioned bio-macromolecules have limited use in treating neurological diseases. Finding effective, safe, and convenient ways to deliver therapeutic molecules into the CNS is thus urgently required. In recent decades, much effort has been expended in the development of drug delivery technologies, of which cell-penetrating peptides (CPPs) have the most promising potential. The present review covers the latest advances in CPP delivery technology, and provides an update on their use in CNS-targeted drug delivery.
Export Options
About this article
Cite this article as:
Zou Li-Li, Ma Jie-Lan, Wang Tao, Yang Tang-Bin and Liu Chang-Bai, Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System, Current Neuropharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570159X11311020006
DOI https://dx.doi.org/10.2174/1570159X11311020006 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synergistic Effect of Immunotherapy and Chemotherapy in Cancers: Perspective in High Grade Glioma Treatment
Letters in Drug Design & Discovery The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging
Current Protein & Peptide Science Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design P53 Mdm2 Inhibitors
Current Pharmaceutical Design New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Current Bioactive Compounds Synthesis and Evaluation of Heterocycles Based Chalcone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging Trends in Malignant Glioma Monoclonal Antibody Therapy
Current Cancer Therapy Reviews Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Novel Tri-substituted Thiazoles Bearing Piperazine Ring: Synthesis and Evaluation of their Anticancer Activity
Letters in Drug Design & Discovery Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets